We are live on ! Find out more
VU

Valence8 US Portfolio holdings

AUM $286M
1-Year Est. Return 22.37%
This Fund
S&P 500
This Quarter Est. Return
-2.5%
1 Year Est. Return
+22.37%
3 Year Est. Return
+53.91%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$208M
AUM Growth
-$32.9M
Cap. Flow
-$25.7M
Cap. Flow %
-12.33%
Top 10 Hldgs %
100%
Holding
63
New
1
Increased
4
Reduced
5
Closed
53

Top Buys

Rank Stock Value
1
IGV icon
iShares Expanded Tech-Software Sector ETF
IGV
+$7.72M
2
EFV icon
iShares MSCI EAFE Value ETF
EFV
+$277K
3
VTV icon
Vanguard Value ETF
VTV
+$135K
4
XLP icon
State Street Consumer Staples Select Sector SPDR ETF
XLP
+$72.6K
5
XLU icon
State Street Utilities Select Sector SPDR ETF
XLU
+$24.4K

Top Sells

Rank Stock Value
1
EWJ icon
iShares MSCI Japan ETF
EWJ
+$3.45M
2
EWU icon
iShares MSCI United Kingdom ETF
EWU
+$3.3M
3
QQQ icon
Invesco QQQ Trust
QQQ
+$2.2M
4
QUAL icon
iShares MSCI USA Quality Factor ETF
QUAL
+$1.92M
5
IQLT icon
iShares MSCI Intl Quality Factor ETF
IQLT
+$1.4M

Sector Composition

Rank Sector Weight
1 Financials 0%
2 Healthcare 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCCC icon
26
CALL
C4 Therapeutics
CCCC
$408M
– –
-10,500
Closed -$59.9K
CLDX icon
27
PUT
Celldex Therapeutics
CLDX
$2.77B
– –
-6,500
Closed -$221K
CRNX icon
28
Crinetics Pharmaceuticals
CRNX
$8.88B
– –
-6,684
Closed -$342K
CRSP icon
29
CALL
CRISPR Therapeutics
CRSP
$4.71B
– –
-13,100
Closed -$615K
ENTA icon
30
Enanta Pharmaceuticals
ENTA
$400M
– –
-19,939
Closed -$207K
ERAS icon
31
Erasca
ERAS
$6.65B
– –
-46,923
Closed -$128K
GOSS icon
32
CALL
Gossamer Bio
GOSS
$83.2M
– –
-20,700
Closed -$20.4K
INDV icon
33
Indivior Pharmaceuticals
INDV
$4.79B
– –
-57,293
Closed -$564K
INSM icon
34
CALL
Insmed
INSM
$23.5B
– –
-6,600
Closed -$482K
INSM icon
35
Insmed
INSM
$23.5B
– –
-7,865
Closed -$574K
IOVA icon
36
CALL
Iovance Biotherapeutics
IOVA
$2.23B
– –
-13,100
Closed -$123K
JANX icon
37
Janux Therapeutics
JANX
$992M
– –
-7,857
Closed -$357K
JANX icon
38
PUT
Janux Therapeutics
JANX
$992M
– –
-2,300
Closed -$104K
JAZZ icon
39
Jazz Pharmaceuticals
JAZZ
$15.5B
– –
-8,969
Closed -$999K
KROS icon
40
Keros Therapeutics
KROS
$211M
– –
-8,025
Closed -$466K
KZR
41
DELISTED
Kezar Life Sciences
KZR
– –
-2,114
Closed -$16.3K
LLY icon
42
Eli Lilly
LLY
$1.05T
– –
-633
Closed -$561K
CYPH
43
Cypherpunk Technologies Inc
CYPH
$75.4M
– –
-18,511
Closed -$47.6K
MRNA icon
44
CALL
Moderna
MRNA
$24.5B
– –
-4,100
Closed -$274K
NKTR icon
45
Nektar Therapeutics
NKTR
$2.31B
– –
-1,740
Closed -$33.9K
NTLA icon
46
Intellia Therapeutics
NTLA
$1.59B
– –
-13,020
Closed -$268K
NUVL
47
DELISTED
Nuvalent
NUVL
– –
-4,115
Closed -$421K
NVO
48
CALL
Novo Nordisk
NVO
$223B
– –
-3,900
Closed -$464K
PCVX icon
49
Vaxcyte
PCVX
$8.12B
– –
-2,468
Closed -$282K
RARE icon
50
CALL
Ultragenyx Pharmaceutical
RARE
$2.88B
– –
-6,900
Closed -$383K
1
2
3

Similar funds

A
Argentarii Cincinnati, Ohio $286M AUM 32.04% 1-Year Est. Return
MC
Muzinich & Co New York $286M AUM 21.05% 1-Year Est. Return
IRAG
Investment Research & Advisory Group Atlanta, Georgia $286M AUM 19.21% 1-Year Est. Return
4WM
44 Wealth Management Eugene, Oregon $286M AUM 18.78% 1-Year Est. Return
MAG
Mayfair Advisory Group Birmingham, Alabama $286M AUM 19.6% 1-Year Est. Return
HMP
HS Management Partners New York $286M AUM 2.97% 1-Year Est. Return
SIIL
Sinvest Investments II Ltd Nassau, New Providence $286M AUM
LCM
Leisure Capital Management Costa Mesa, California $286M AUM 26.75% 1-Year Est. Return

Valence8 US's Q4 2024 Portfolio in Review

As of Q4 2024, Valence8 US held 63 positions worth $208M, down 14% from $241M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Valence8 US withdrew a net $25.7M in Q4 2024, closing 53 positions and reducing 5 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $999K position sold in full.

By sector, the portfolio is most concentrated in Financials at 0% of assets, down from 0.02% a quarter earlier, followed by Healthcare.

Against the trend, Valence8 US opened a new position in iShares Expanded Tech-Software Sector ETF worth $7.8M.

  • Valence8 US's largest Q4 2024 buy was iShares Expanded Tech-Software Sector ETF: 77,909 shares worth $7.8M.
  • Valence8 US added most to iShares MSCI EAFE Value ETF in Q4 2024, an estimated $277K increase.
  • Valence8 US's biggest Q4 2024 reduction was iShares MSCI Japan ETF, cutting an estimated $3.45M.
  • Valence8 US fully exited Jazz Pharmaceuticals in Q4 2024, selling an estimated $999K.
  • Valence8 US's ten largest holdings make up 100% of its $208M portfolio in Q4 2024.
  • Valence8 US opened 1 new position and closed 53 in Q4 2024.
  • Valence8 US's portfolio value fell 14% quarter-over-quarter to $208M.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.